BCR190-RT48
BCR-ABL1 p190(mbcr) Detection Kit
Quantity: 48 Tests
£1,274.00
The geneMAP™ BCR-ABL1 p190(mbcr) Detection Kit intended for the quantification of BCR-ABL1 p190(e1a2) transcripts in bone marrow or peripheral blood samples of Ph-positive acute lymphoblastic leukemia (ALL) patients previously diagnosed with a BCR-ABL1 mbcr fusion gene event. The test is intended to evaluate the level of molecular response. This test can be used to monitor Minimal Residual Disease (MRD) in patients undergoing therapy.
- Superior Analytical Sensitivity: Achieves a Log4 reduction, providing high sensitivity in detecting the BCR-ABL1 p190 fusion transcript.
- One-Step RT-qPCR Technology: Simplifies the testing process, making it fast and easy to use while ensuring precise results.
- Accurate Relative Quantitation: Utilizes multiplex PCR to quantify fusion transcripts relative to ABL1, enhancing diagnostic accuracy.
- Compatibility: Works with FAM and VIC/HEX dual-color real-time PCR instruments, offering broad applicability.
- CE-IVD Certification: Meets European standards for in vitro diagnostic medical devices, ensuring reliability and quality.
- Leukemia Diagnosis: Essential for identifying the BCR-ABL1 p190 fusion transcript, a key genetic marker in certain leukemia types.
- Treatment Monitoring: Plays a significant role in monitoring the effectiveness of leukemia treatments by quantifying the presence of the BCR-ABL1 p190 transcript over time.
- Technology: One-step RT-qPCR with multiplex PCR for relative quantitation of BCR-ABL1 fusion transcripts.
- Sensitivity: Superior analytical sensitivity with a Log4 reduction capability.
- Compatibility: Suitable for use with real-time PCR instruments capable of detecting FAM and VIC/HEX.
- Certification: CE-IVD marked, indicating its suitability for in vitro diagnostic use within the European Union.
Why Choose Clent
We strive to enable our customers to focus on the results of their work, rather than the tools they use. Need to speak with a member of our team? Get in touch today.
